Q2 2025 Codexis Inc Earnings Call Transcript
Key Points
- Codexis Inc (CDXS) reported strong second-quarter results with revenue above consensus and operating loss halved compared to Q2 2024.
- The company maintained a solid cash balance and significantly improved operating margins.
- There is strong interest in the ECO Synthesis platform, with over 30 ongoing customer engagements, indicating potential for future growth.
- Codexis Inc (CDXS) has a proven track record in delivering high-quality enzymes, which has fueled expansion in early biocatalysis engagements.
- The company is exploring options to expand its bandwidth to support early projects and maximize returns from the ECO platform.
- Codexis Inc (CDXS) anticipates continued revenue variability due to the unpredictability of its heritage business.
- The company faces challenges in meeting the rapidly growing demand for the ECO platform, which may exceed its current supply capabilities.
- Research and development expenses increased due to higher headcount and internal reclassification of employees.
- Despite improvements, the company still reported a net loss of $13.3 million for the second quarter of 2025.
- There is a need for careful management of expenses as ECO revenues begin to materialize, with a focus on balancing resource allocation.
Welcome to Codexis' second-quarter 2025 earning conference call. (Operator Instructions) Please note this event is being recorded.
And now, I'll turn the call over to Georgia Erbez, Chief Financial Officer. Please go ahead.
Thank you, operator. With me today are Dr. Steven Dilly, Codexis' Chairman and Chief Executive Officer; and Kevin Norrett, Chief Operating Officer.
During this call, we will be making a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our guidance for 2025 revenue, anticipated milestones including product launches, pilot scale manufacturing, and paths to scale up, technical milestones and public announcements related thereto, as well as our strategies and prospects for revenue growth, path to profitability, and successful execution of current and future programs and partnerships.
To the extent the statements contained in this call are not descriptions of historical facts regarding Codexis
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
